NBIX

Neurocrine Biosciences, Inc. [NBIX] Stock Forecast

Q: What is Neurocrine Biosciences, Inc. stock symbol ?

Neurocrine Biosciences, Inc. is a US stock, located in San diego of Ca and trading under the symbol NBIX

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

NBIX Stock Summary

Earnings have grown 26.76% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

NBIX has more than 22 years of cash runway (268 months)

Earnings are expected to fall -100% next year

Profit margins (0.11%) are lower than the previous year (0.13%)

Top 10 Correlated ETFs

NBIX

Top 10 Correlated Stocks

NBIX

In the News

NBIX Financial details

Company Rating

Strong Buy

Market Cap

13.4B

Income

249.7M

Revenue

1.89B

Book val./share

22.68

Cash/share

10.48

Dividend

Dividend %

Employees

1.4K

Optionable

Shortable

Yes

Earnings

01 May 2024

P/E

68.54

Forward P/E

PEG

11.87

P/S

7.36

P/B

6.54

P/C

12.71

P/FCF

34.15

Quick Ratio

2.19

Current Ratio

2.39

Debt / Equity

0.19

LT Debt / Equity

0.12

EPS (TTM)

2.54

EPS next Y

EPS next Q

EPS this Y

59.01%

EPS next Y

EPS next 5Y

EPS last 5Y

44.96%

Revenue last 5Y

19.08%

Revenue Q/Q

3.29%

EPS Q/Q

76.47%

SMA20

-3.57%

SMA50

-3.57%

SMA100

21.62%

Inst Own

74.07%

Inst Trans

0.79%

ROA

ROE

11%

ROC

0.09%

Gross Margin

98%

Oper. Margin

11%

Profit Margin

11%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

89.04-148.37

52W High

-9.98%

52W Low

+49.7%

RSI

Rel Volume

0.65

Avg Volume

885.23K

Volume

571.09K

Perf Week

-3.52%

Perf Month

-1.55%

Perf Quarter

23.45%

Perf Half Y

17.28%

Beta

0.277

Volatility

1.24%, 2.94%

Prev Close

Price

133.23

Change

0.09%

NBIX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	8.6	11.23	11.98	15.54	19.32
Net income per share	0.4	4.37	0.95	1.61	2.56
Operating cash flow per share	1.66	2.45	2.71	3.54	3.99
Free cash flow per share	1.5	2.34	2.46	3.37	3.7
Cash per share	7.32	15.2	7.52	10.33	10.56
Book value per share	6.95	12.1	14.52	17.83	22.85
Tangible book value per share	6.95	12.1	14.52	17.44	22.48
Share holders equity per share	6.95	12.1	14.52	17.83	22.85
Interest debt per share	5.76	4.89	5.1	2.82	4.43
Market cap	9.85B	8.92B	8.06B	11.44B	12.87B
Enterprise value	10.23B	8.53B	8.16B	11.44B	13.05B
P/E ratio	266.19	21.91	89.92	74.06	51.55
Price to sales ratio	12.5	8.53	7.11	7.69	6.82
POCF ratio	64.77	39.05	31.41	33.71	33.02
PFCF ratio	71.73	41.01	34.56	35.44	35.6
P/B Ratio	15.46	7.92	5.86	6.7	5.77
PTB ratio	15.46	7.92	5.86	6.7	5.77
EV to sales	12.98	8.16	7.2	7.69	6.92
Enterprise value over EBITDA	45.16	26.06	39.25	45.95	31.36
EV to operating cash flow	67.29	37.35	31.8	33.71	33.47
EV to free cash flow	74.52	39.22	34.99	35.44	36.09
Earnings yield	0	0.05	0.01	0.01	0.02
Free cash flow yield	0.01	0.02	0.03	0.03	0.03
Debt to equity	0.78	0.38	0.33	0.15	0.19
Debt to assets	0.38	0.24	0.22	0.11	0.13
Net debt to EBITDA	1.69	-1.19	0.48	0	0.43
Current ratio	1.47	5.45	3.96	2.7	2.45
Interest coverage	6.85	9.72	7.63	35.07	54.54
Income quality	4.11	0.56	2.86	2.2	1.56
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.25	0.26	0.29	0.31	0.3
Intangibles to total assets	0	0	0	0.02	0.01
Capex to operating cash flow	-0.1	-0.05	-0.09	-0.05	-0.07
Capex to revenue	-0.02	-0.01	-0.02	-0.01	-0.01
Capex to depreciation	-1.98	-1.27	-2.15	-1.06	-1.33
Stock based compensation to revenue	0.1	0.1	0.12	0.12	0.1
Graham number	7.95	34.51	17.59	25.43	36.25
ROIC	0.14	0.74	0.09	0.09	0.06
Return on tangible assets	0.03	0.23	0.04	0.07	0.08
Graham Net	1.15	10.08	1.77	6.35	3.69
Working capital	265.7M	829.7M	727M	915.8M	952.2M
Tangible asset value	636.9M	1.13B	1.37B	1.67B	2.2B
Net current asset value	161.9M	407.7M	274.3M	792.6M	587.6M
Invested capital	0.78	0.38	0.33	0.15	0.19
Average receivables	91.41M	141.84M	171.3M	267.75M	394.65M
Average payables	30.01M	42.81M	45.45M	63.9M	92.6M
Average inventory	14.08M	22.64M	29.25M	32.8M	36.7M
Days sales outstanding	58.62	54.83	59.73	85.81	84.97
Days payables outstanding	2.28K	1.42K	1.31K	1.2K	1K
Days of inventory on hand	852.72	1.01K	778.5	552.22	352.13
Receivables turnover	6.23	6.66	6.11	4.25	4.3
Payables turnover	0.16	0.26	0.28	0.3	0.36
Inventory turnover	0.43	0.36	0.47	0.66	1.04
ROE	0.06	0.36	0.07	0.09	0.11
Capex per share	-0.16	-0.12	-0.25	-0.17	-0.29

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	4.28	4.33	4.64	5.09	5.24
Net income per share	0.92	-0.79	0.98	0.85	1.5
Operating cash flow per share	1.48	-1.29	1.84	2.17	1.26
Free cash flow per share	1.47	-1.38	1.77	2.09	1.2
Cash per share	10.27	10.8	10.01	11.19	10.48
Book value per share	17.73	17.35	18.99	20.45	22.68
Tangible book value per share	17.35	16.96	18.61	20.09	22.32
Share holders equity per share	17.73	17.35	18.99	20.45	22.68
Interest debt per share	2.74	2.88	2.66	2.62	4.36
Market cap	11.5B	9.83B	9.2B	11.01B	12.97B
Enterprise value	11.5B	10.18B	9.3B	10.98B	13.14B
P/E ratio	32.31	-32.08	24.09	33.13	21.95
Price to sales ratio	27.92	23.38	20.33	22.08	25.17
POCF ratio	80.43	-78.5	51.25	51.95	104.98
PFCF ratio	81.46	-73.51	53.26	53.88	109.78
P/B Ratio	6.74	5.83	4.97	5.5	5.81
PTB ratio	6.74	5.83	4.97	5.5	5.81
EV to sales	27.92	24.21	20.55	22	25.51
Enterprise value over EBITDA	111.24	342.72	126.39	77.73	84.25
EV to operating cash flow	80.43	-81.3	51.79	51.77	106.42
EV to free cash flow	81.46	-76.13	53.83	53.7	111.28
Earnings yield	0.01	-0.01	0.01	0.01	0.01
Free cash flow yield	0.01	-0.01	0.02	0.02	0.01
Debt to equity	0.15	0.17	0.14	0.13	0.19
Debt to assets	0.11	0.12	0.1	0.09	0.13
Net debt to EBITDA	0	11.79	1.34	-0.27	1.14
Current ratio	2.7	3.83	2.57	2.39	2.45
Interest coverage	94	-103.82	56.62	128.36	136.64
Income quality	1.61	1.63	1.88	2.55	0.84
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0.29	0.33	0.32	0.29	0.27
Intangibles to total assets	0.02	0.02	0.01	0.01	0.01
Capex to operating cash flow	-0.01	0.07	-0.04	-0.04	-0.04
Capex to revenue	0	-0.02	-0.02	-0.02	-0.01
Capex to depreciation	-0.41	-1.7	-1.33	-1.38	-0.95
Stock based compensation to revenue	0.11	0.09	0.15	0.1	0.07
Graham number	19.2	17.55	20.44	19.76	27.68
ROIC	0.04	-0.04	0.03	0.04	0.04
Return on tangible assets	0.04	-0.03	0.04	0.03	0.05
Graham Net	6.32	7.04	5.36	5.89	3.67
Working capital	915.8M	1.06B	914.1M	958.3M	952.2M
Tangible asset value	1.67B	1.65B	1.82B	1.97B	2.2B
Net current asset value	792.6M	757.5M	736.5M	803.8M	587.6M
Invested capital	0.15	0.17	0.14	0.13	0.19
Average receivables	325.6M	370.8M	389.6M	402.7M	428.55M
Average payables	187.05M	216M	373.65M	242.7M	101.35M
Average inventory	36.05M	34.25M	32.55M	30.25M	33.55M
Days sales outstanding	76.46	83.83	77.06	75.38	76.74
Days payables outstanding	891.82	3.77K	3.06K	753.75	1.15K
Days of inventory on hand	410.26	353.65	248.09	231.43	405.53
Receivables turnover	1.18	1.07	1.17	1.19	1.17
Payables turnover	0.1	0.02	0.03	0.12	0.08
Inventory turnover	0.22	0.25	0.36	0.39	0.22
ROE	0.05	-0.05	0.05	0.04	0.07
Capex per share	-0.02	-0.09	-0.07	-0.08	-0.05

NBIX Frequently Asked Questions

What is Neurocrine Biosciences, Inc. stock symbol ?

Neurocrine Biosciences, Inc. is a US stock , located in San diego of Ca and trading under the symbol NBIX

What is Neurocrine Biosciences, Inc. stock quote today ?

Neurocrine Biosciences, Inc. stock price is $133.23 today.

Is Neurocrine Biosciences, Inc. stock public?

Yes, Neurocrine Biosciences, Inc. is a publicly traded company.

Something similar

Top by Market Cap

M&M.NS

NVD.DE

Company Profile

Volume Average 885.23K
Market Capitalization 13.4B
Employee 1.4K
CEO Dr. Kevin C. Gorman Ph.D.
Headquarters San Diego,CA,US
IPO Date 1996-05-23
Website https://www.neurocrine.com

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.